Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biodetection

    DoD Looks to Panther Fusion System for High-Throughput Coronavirus Diagnostics

    By Global Biodefense StaffMarch 27, 2020
    Share
    Facebook LinkedIn Reddit Email

    The U.S. Army Medical Research Acquisition Activity (USAMRAA) announced a contract action to Hologic, Inc. this month to acquire the Panther Fusion open access platform for the clinical Panther system currently deployed within Diagnostics and Countermeasures Branch (DCB) at Walter Reed Army Institute of Research (WRAIR).

    The Panther Fusion open access platform is a high-throughput platform technology that can be implemented for rapid coronavirus detection, Hologic pan-coronavirus (OC43, HKU1, NC63, 229E) and Gen Probe SARS-CoV-2 EUA assays.


    Related: BARDA Backs Hologic’s High-Throughput COVID-19 Diagnostic


    The deployment of the U.S. CDC Emergency Use Authorization assay has been plagued by problems with reagents, thus delaying implementation of testing in both civilian Department of Defense laboratories. The current SARS-CoV-2 diagnostic assays available within the U.S are executed on low throughput systems within both civilian and U.S. Military laboratory systems (30-60 patient tests per 8 hour period); thus limiting the ability to scale up to high-volume testing required in the dynamically changing epidemic situation.

    This is of great concern to U.S. Army senior leaders; specifically, with regard to the lack of high throughput available to detect this infection in U.S. Military Operational and Deployed Forces. The identification of 77 SARS-CoV-2 infected U.S. citizens and two U.S. Service Members (1 in South Korea, 1in Italy) has critically underscored the mission essential requirement for robust, expanded test capability within the U.S. Military.

    The Pentagon confirmed in a briefing Mar. 26 that the active duty COVID-19 case count had quadrupled in the past week, bringing DoD totals to 280 members of the military, 62 contractors, 134 Defense Department civilians and 98 military dependents positive for COVID-19.

    ASPR Coronavirus COVID-19 Editor Pick HHS Magazine Edition 11 April 2020 Rapid Diagnostics SARS-CoV-2 WRAIR
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleUniversity of Washington Releases Predictive Model for Hospital Utilization and Deaths Due to COVID-19
    Next Article Abbott Receives EUA for Rapid Point-of-Care COVID-19 Diagnostic

    Related Stories

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023

    Ontario Supporting $165M Investment to Secure Critical PPE Supply

    December 2, 2023

    Black Death Impact on Microbiome May Have Contributed to Modern-Day Chronic Diseases

    November 29, 2023

    Inflammatix Completes Development for Acute Infection and Sepsis Test System

    November 15, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Dec 5
    10:45 am - 3:00 pm EST

    Meeting the Moment: Biodefense Policy, Procurement, and Public Health

    Dec 6
    Virtual Event Virtual Event
    6:00 am - 7:00 am EST

    AMR One Health Priority Research Agenda: Transmission

    Mar 12
    Virtual Event Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.